CompletedPHASE1, PHASE2NCT05890794
Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia
Studying Adult hypophosphatasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AM-Pharma
- Principal Investigator
- Dr SeefriedOsteologie / Klinische Studieneinheit, Orthopädische Klinik - KLH, Würzburg, Germany
- Intervention
- Ilofotase Alfa, 0.8 mg/kg(biological)
- Enrollment
- 12 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2023 – 2023
Study locations (1)
- Osteologie / Klinische Studieneinheit, Orthopädische Klinik - KLH, Würzburg, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05890794 on ClinicalTrials.govOther trials for Adult hypophosphatasia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07390240The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in RussiaAstraZeneca
- RECRUITINGNCT06574282Characteristics of Hypophosphatasia in Adult Patients in Rheumatology and Their Value in Developing an Algorithm to HPP-diagnosis - the COHIR Multi-center StudyUniversity of Bonn
- ACTIVE NOT RECRUITINGPHASE3NCT06079281Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase AlfaAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT05596539Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)Assistance Publique - Hôpitaux de Paris
- RECRUITINGNCT02237625Natural History Study of Patients With Hypophosphatasia (HPP)Duke University